The glycemic benefits of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors in individuals with type 1 diabetes (T1D) have been consistently reported in the few randomized controlled trials conducted to date, namely the DEPICT (Dandona et al., 2017, 2018; Mathieu et al., 2018, 2020), EASE (Rosenstock et al., 2018), and inTandem (Buse et al., 2018; Danne et al., 2018; Garg et al., 2017; Sridhar et al., 2023) trials. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.